Cargando…
Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002695/ http://dx.doi.org/10.1186/1750-9378-5-S1-A36 |
| _version_ | 1782193764885856256 |
|---|---|
| author | Nayar, Utthara Lu, Pin Vider, Jelena Cerchietti, Leandro Chiosis, Gabriela Wang, Lynn Blasberg, Ronald Cesarman, Ethel |
| author_facet | Nayar, Utthara Lu, Pin Vider, Jelena Cerchietti, Leandro Chiosis, Gabriela Wang, Lynn Blasberg, Ronald Cesarman, Ethel |
| author_sort | Nayar, Utthara |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-3002695 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-30026952010-12-16 Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma Nayar, Utthara Lu, Pin Vider, Jelena Cerchietti, Leandro Chiosis, Gabriela Wang, Lynn Blasberg, Ronald Cesarman, Ethel Infect Agent Cancer Meeting Abstracts BioMed Central 2010-10-11 /pmc/articles/PMC3002695/ http://dx.doi.org/10.1186/1750-9378-5-S1-A36 Text en Copyright ©2010 Nayar et al; licensee BioMed Central Ltd. |
| spellingShingle | Meeting Abstracts Nayar, Utthara Lu, Pin Vider, Jelena Cerchietti, Leandro Chiosis, Gabriela Wang, Lynn Blasberg, Ronald Cesarman, Ethel Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title_full | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title_fullStr | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title_full_unstemmed | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title_short | Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma |
| title_sort | hsp90 is a viable therapeutic target in the treatment of kshv-associated primary effusion lymphoma |
| topic | Meeting Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002695/ http://dx.doi.org/10.1186/1750-9378-5-S1-A36 |
| work_keys_str_mv | AT nayarutthara hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT lupin hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT viderjelena hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT cerchiettileandro hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT chiosisgabriela hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT wanglynn hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT blasbergronald hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma AT cesarmanethel hsp90isaviabletherapeutictargetinthetreatmentofkshvassociatedprimaryeffusionlymphoma |